Eblasakimab found to open lung airways of COPD patient samples

Treatment with the anti-inflammatory medication eblasakimab opened the airways of lung samples from people with chronic obstructive pulmonary disorder (COPD) in laboratory experiments. The findings were shared by Aslan Pharmaceuticals, the company that’s developing eblasakimab, in an oral presentation at the Dermatology Drug Development Summit, held recently in…

Reasons Seen for COPD Patients’ Susceptibility to Severe COVID-19

The infection rate of SARS-CoV-2, the virus that causes COVID-19, is 24 times higher in lab-grown airway cells from people with chronic obstructive pulmonary disease (COPD) than in those from healthy people, a study shows. This increased susceptibility to infection, which makes severe outcomes more likely, was associated with…